Comparative Pharmacology
Head-to-head clinical analysis: LARIAM versus QUININE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIAM versus QUININE SULFATE.
LARIAM vs QUININE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.
Quinine sulfate is a blood schizonticide effective against the asexual erythrocytic forms of Plasmodium spp. It interferes with the parasite's ability to digest hemoglobin, leading to accumulation of toxic heme and parasite death. Quinine also has mild analgesic and antipyretic effects, and may depress cardiac conduction and contractility.
For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.
324 mg orally every 8 hours for 7 days (for treatment of chloroquine-resistant falciparum malaria, in combination with other antimalarials).
None Documented
None Documented
Terminal elimination half-life: approximately 3 weeks (range 13–33 days); prolonged due to extensive tissue distribution and slow release from erythrocytes.
Terminal elimination half-life: 18 hours (range 16-21 hours) in healthy adults; prolonged in renal impairment (up to 25-30 hours) and severe hepatic impairment.
Hepatic metabolism (primarily CYP3A4) followed by biliary/fecal elimination; ~40% unchanged in feces, ~9% as metabolites in urine, minimal renal excretion of parent drug (<5%).
Renal: 20% unchanged; hepatic metabolism (CYP3A4, CYP2C9) accounts for 80% with metabolites (primarily 3-hydroxyquinine) excreted renally and fecally. Biliary excretion is minor (<5%).
Category C
Category D/X
Antimalarial
Antimalarial